Pre-made Gevokizumab benchmark antibody ( Whole mAb, anti-IL1B therapeutic antibody, Anti-IL-1/IL1-BETA/IL1F2/IL1beta Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Gevokizumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta),[1] a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-241-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Gevokizumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody
INN Name	Gevokizumab
Target	IL1B
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	4g6k:HL/4g6m:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	IRIS;National Eye Institute;North Shore-Long Island Jewish Health System;Novartis;Servier;University of Zurich;XOMA
Conditions Approved	na
Conditions Active	Uveitis;Acne vulgaris;Acute coronary syndromes;Diabetic nephropathies;Giant cell arteritis;Labyrinthitis;Myositis;Osteoarthritis;Schnitzler syndrome;Scleritis;Colorectal cancer;Renal cell carcinoma
Conditions Discontinued	Rheumatoid arthritis;Cancer;Gout;Juvenile rheumatoid arthritis;Type 1 diabetes mellitus;Type 2 diabetes mellitus;Pyoderma
Development Tech	na